Features of treatment and rehabilitation of COVID-19 patients with ischemic stroke
Author:
G.S. RAKHIMBAYEVA, SH.R. GAZIEVA, M.K. ATANIYAZOV, F.H. MURATOV, D.S. TOLIPOV, U.D. SHODIEV
Tashkent Medical Academy, Tashkent, Republic of Uzbekistan
Summary:
The development of COVID-19 is associated with damage to various organs and organ systems, including the development of acute ischemic stroke (AI). The article examines modern ideas about the pathogenesis of AI in COVID-19. The data on the choice of optimal therapy for patients with acute AI and COVID-19, as well as on the possibility of improving the effectiveness of rehabilitation measures, are analyzed. Information is provided on the efficacy of the drug Mexidol in patients with AI and COVID-19. Keywords: ischemic stroke, COVID-19, treatment, rehabilitation, Mexidol.
Features of treatment and rehabilitation of COVID-19 patients with ischemic stroke
Author:
G.S. RAKHIMBAYEVA, SH.R. GAZIEVA, M.K. ATANIYAZOV, F.H. MURATOV, D.S. TOLIPOV, U.D. SHODIEV
Tashkent Medical Academy, Tashkent, Republic of Uzbekistan
Summary:
The development of COVID-19 is associated with damage to various organs and organ systems, including the development of acute ischemic stroke (AI). The article examines modern ideas about the pathogenesis of AI in COVID-19. The data on the choice of optimal therapy for patients with acute AI and COVID-19, as well as on the possibility of improving the effectiveness of rehabilitation measures, are analyzed. Information is provided on the efficacy of the drug Mexidol in patients with AI and COVID-19. Keywords: ischemic stroke, COVID-19, treatment, rehabilitation, Mexidol.
Features of treatment and rehabilitation of COVID-19 patients with ischemic stroke
This article is in “Library” – “Covid-19” section.
Author:
G.S. RAKHIMBAYEVA, SH.R. GAZIEVA, M.K. ATANIYAZOV, F.H. MURATOV, D.S. TOLIPOV, U.D. SHODIEV
Tashkent Medical Academy, Tashkent, Republic of Uzbekistan
Oxidative stress in the pathogenesis of stroke and its correction
Author:
M.YU. MARTYNOV1,2, M.V. ZHURAVLEVA3,4, N.S. VASYUKOVA5, E.V. KUZNETSOVA6, T.R. KAMENEVA7
1Pirogov Russian National Research Medical University, Moscow, Russia;
2Federal Center of Brain Research and Neurotechnologies, Moscow, Russia;
3Research Center for Examination of Medical Devices, Moscow, Russia;
4Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
5Skriabin and Kovalenko Institute of Experimental Veterinary Medicine, Moscow, Russia;
6Research Institute for Healthcare and Medical Management, Moscow, Russia;
7Konchalovsky City Clinical Hospital, Moscow, Russia
Summary:
We reviewed the role of oxidative stress (OS) in the pathogenesis of ischemic (IS) and hemorrhagic stroke (HS). OS plays a major role in programmed cell death, increased permeability of the blood-brain barrier, astroglial and microglial activation, and local inflammatory response. We also reviewed the current state of neuro- and cytoprotection studies and their translation in clinical practice. With respect to experimental and clinical data the efficacy of long term administration of multimodal cytoprotective drug with antioxidant effect — ethylmethylhydroxypyridine succinate (Mexidol) is discussed during the acute and early recovery period after stroke. Keywords: stroke, reperfusion, oxidative stress, programmed cell death, apoptosis, ferroptosis, hemoglobin, neuroprotection, ethylmethylhydroxypyridine succinate, Mexidol.
Cognitive disorders of vascular genesis in the practice of a therapist
Author:
P.R. KAMCHATNOV1, R.A. CHEREMIN2, L.A. SKIPETROVA2, A.V. CHUGUNOV1
1N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
2Center of Speech Pathology and Neurorehabilitation of the Moscow Healthcare Department
Summary:
Cognitive impairment (CI) is a widespread clinical syndrome, with which specialists of various profiles often meet in outpatient settings. Diagnosis of CI is a responsible task, the correct solution of which requires a comprehensive analysis of anamnestic information, the nature of the clinical picture, the results of laboratory and instrumental examination. Cerebrovascular diseases are a common cause of CI. The article discusses the issues of management of patients with coronary artery disease, in particular, the main aspects of correction of cardiovascular risk factors, the choice of optimal drug therapy are considered. Information is provided on the possibility of using the drug Mexidol for the treatment of this contingent of patients. The results of studies devoted to the study of the possibility of using Mexidol in patients with chronic disorders of cerebral circulation with CI are analyzed. Key words: chronic cerebral ischemia, chronic cerebrovascular diseases, small cerebral artery disease, cognitive impairment, Mexidol.
Oxidative stress in the pathogenesis of stroke and its correction
This article is in “Library” – “Neurology” - "CCT" section.
Author:
M.YU. MARTYNOV1,2, M.V. ZHURAVLEVA3,4, N.S. VASYUKOVA5, E.V. KUZNETSOVA6, T.R. KAMENEVA7
1Pirogov Russian National Research Medical University, Moscow, Russia;
2Federal Center of Brain Research and Neurotechnologies, Moscow, Russia;
3Research Center for Examination of Medical Devices, Moscow, Russia;
4Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
5Skriabin and Kovalenko Institute of Experimental Veterinary Medicine, Moscow, Russia;
6Research Institute for Healthcare and Medical Management, Moscow, Russia;
7Konchalovsky City Clinical Hospital, Moscow, Russia
Cognitive disorders of vascular genesis in the practice of a therapist
This article is in “Library” – “Therapy” - section.
Author:
P.R. KAMCHATNOV1, R.A. CHEREMIN2, L.A. SKIPETROVA2, A.V. CHUGUNOV1
1N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
2Center of Speech Pathology and Neurorehabilitation of the Moscow Healthcare Department
Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia
This article is in “Library” – “Neurology” – “CCR: Chronic Cerebrovascular Disorder” section.
Author:
M.V. ZHURAVLEVA1,2, P.R. KAMCHATNOV3, N.S. VASYUKOVA4, V.V. ARKHIPOV1, E.V. KUZNETSOVA5, T.R. KAMENEVA6, S.YU. SEREBROVA1,2
1Research Center for Examination of Medical Devices, Moscow, Russia;
2Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3Pirogov Russian National Research Medical University, Moscow, Russia;
4Skriabin and Kovalenko Institute of Experimental Veterinary Medicine, Moscow, Russia;
5Research Institute for Healthcare and Medical Management, Moscow, Russia;
6Konchalovsky City Clinical Hospital, Moscow, Russia
Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia
Author:
M.V. ZHURAVLEVA1,2, P.R. KAMCHATNOV3, N.S. VASYUKOVA4, V.V. ARKHIPOV1, E.V. KUZNETSOVA5, T.R. KAMENEVA6, S.YU. SEREBROVA1,2
1Research Center for Examination of Medical Devices, Moscow, Russia;
2Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3Pirogov Russian National Research Medical University, Moscow, Russia;
4Skriabin and Kovalenko Institute of Experimental Veterinary Medicine, Moscow, Russia;
5Research Institute for Healthcare and Medical Management, Moscow, Russia;
6Konchalovsky City Clinical Hospital, Moscow, Russia
Summary:
Chronic cerebral ischemia (CCI) is a common syndrome that, in the absence of adequate therapy, is characterized by a progressive course, an increase in cognitive, emotional, motor and other disorders, eventually leading to persistent disability of the patient. In the treatment of patients with CCI, the use of drugs with a multimodal neuroprotective effect is indicated. The results of the analysis of a series of clinical trials of the drugs Mexidol and Mexidol FORTE in patients with CCI are presented. The effects in relation to cognitive, emotional, asthenic, vegetative and other manifestations of CCI are considered. It is concluded that it is advisable to consistently use the drugs Mexidol and Mexidol FORTE in such patients. Keywords: chronic cerebral ischemia, cognitive impairment, Mexidol, emotional disorders, treatment.
Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO)
This article is in “Library” – “Neurology” - "CCR: Chronic Cerebrovascular Disorder" section.
Author:
V.V. ZAKHAROV1, O.N. TKACHEVA2,3, E.A. MKHITARYAN2,3, A.I. FEDIN2
1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2Pirogov Russian National Research Medical University , Moscow, Russia;
3Russian Clinical and Research Center of Gerontology, Pirogov Russian National Research Medical University , Moscow, Russia